Finanzen von PureTech Health PLC (PRTC)PRTCPureTech Health PLC

PureTech Health PLC (PRTC) generates its revenue primarily from Internal, which accounts for 100.0% of total sales, equivalent to $288.00K. Understanding this concentration is critical for investors evaluating how PRTC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, PureTech Health PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2589.47%, while the net margin is -2419.34%. These profitability ratios, combined with a Return on Equity (ROE) of 14.65%, provide a clear picture of how effectively PRTC converts its operational activities into shareholder value.

In the context of the broader market, PRTC competes directly with industry leaders such as NAUT and DMAC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, PRTC's gross margin of 100.00% stands against NAUT's 92.11% and DMAC's N/A. Such benchmarking helps identify whether PureTech Health PLC is trading at a premium or discount relative to its financial performance.

No usable latest-quarter financial data was provided, so recent revenue, earnings, and growth trends cannot be assessed. The financial snapshot returned an error, and the latest quarter season is not available from the data provided.